Eli Lilly and Co's antibody drug combination has received an emergency use approval in India for the treatment of mild-to-moderate Covid-19, bolstering the country's arsenal of medicines to tackle the second wave. A combination of the U.S. drugmaker's monoclonal antibodies bamlanivimab and etesevimab has been given approval for restricted use, the company's Indian unit said.

from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/3caGi0i
via i